Immune checkpoint inhibition by anti-PD-1 or CD137 co-stimulation enhances cytotoxicity towards CD30+ tumors mediated by the bispecific tetravalent CD30/CD16A TandAb AFM13

Abstract

AFM13 is an NK-cell-engaging CD30/CD16A bispecific tetravalent TandAb antibody currently in Phase 2 clinical development in Hodgkin lymphoma (HL) and CD30+ malignancies. Immune checkpoints inhibitors have demonstrated clinical efficacy in a variety of cancers, including HL. NK cells are regulated by a number of check-points, prompting us to investigate the combination of AFM13 with several immune-modulatory antibodies. In previous experiments we were able to demonstrate higher efficacy of AFM13 than several immuno-modulatory antibodies in monotherapy and strong synergy between AFM13 and an anti-PD-1 antibody in vitro, as well as in vivo in PDX models of human CD30+ HL tumors. In order to investigate the underlying immunological mechanisms we employed the same PDX model by implanting tumor fragments derived from surgical specimens of HL patients in immunodeficient mice. After establishing tumors, mice were reconstituted with autologous patient-derived PBMC and treated with AFM13 alone and in combination with anti-PD-1 weekly for a total of three weeks. Tumor size, tumor-infiltrating human lymphocytes, myeloid cells and intratumoral cytokines were evaluated on days 30, 44, and 58, i.e. 12 and 30 days after treatment start. While monotherapy with AFM13 was reproducibly more potent than anti-PD-1, significant synergy was observed when both agents were combined. Analysis of the tumors on day 58 revealed a strong correlation between tumor growth inhibition and levels of tumor-infiltrating NK-cells, T-cells, myeloid cells and intratumoral cytokines such as IP-10. In contrast to anti-PD-1 monotherapy, which only induced T-cell infiltration, AFM13 monotherapy was able to induce infiltration of NK- and T-cells in the tumors, with the combination further enhancing infiltration of both. AFM13 induced stronger infiltration of macrophages than anti-PD-1, which was also increased by the combination of both agents, thereby further supporting crosstalk between innate and adaptive immunity. Furthermore, tumor analyses at earlier time-points (days 30 and 44) showed that the initial immune response is characterized by NK-cell infiltration and activation, as well as infiltration of macrophages, whilst the adaptive immune response by T-cells and activated dendritic cells was more pronounced on day 58. Combining AFM13 and anti-PD-1 augments infiltration and activation of all immune cell subpopulations.

In conclusion, our data show strong synergistic antitumor efficacy when AFM13 is combined with anti-PD-1 checkpoint blockade in HL PDX models, mediated by tumor-infiltrating lymphocytes, macrophages and dendritic cells, and provide strong evidence for crosstalk between innate and adaptive immunity induced by AFM13-recoated human NK-cells.

AFM13

Mechanism of action of the CD30/CD16A TandAb

Combination of AFM13 with checkpoint blockade or co-stimulation in vivo

In vivo activity of AFM13 in combinations with CPIs in a Hodgkin lymphoma PDX model

AFM13-mediated immune crosstalk not only involves NK- and T-cells, but also macrophages and dendritic cells in in vivo PDX models of Hodgkin lymphoma

Key results

- Combining AFM13 and anti-PD-1 strongly enhanced NK-cell-mediated CD30+ target cell lysis in vitro
- AFM13-induced tumor lysis was substantially enhanced by PD-1 blockade in in vivo PDX models of Hodgkin lymphoma
- AFM13-mediated anti-tumor efficacy results from innate to adaptive immune crosstalk and involves not only NK-cells and T-cells, but also macrophages and dendritic cells, thus forming an integrated immune response

Reference:

# Corresponding author